Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:CARMNASDAQ:IKNANASDAQ:INCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.20-1.6%$1.06$0.86▼$3.60$72.69M0.05288,110 shs382,916 shsCARMCarisma Therapeutics$0.44-12.2%$0.26$0.14▼$1.90$18.43M1.633.80 million shs3.88 million shsIKNAIkena Oncology$1.36-0.7%$1.22$0.97▼$1.94$65.63M0.45134,793 shs26,724 shsINCRInterCure$1.52+1.3%$1.51$1.17▼$2.62$69.27M1.2226,295 shs20,297 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+12.15%+16.50%0.00%-48.50%CARMCarisma Therapeutics0.00%-2.33%+139.34%+6.62%-57.17%IKNAIkena Oncology0.00%+0.74%+18.26%-0.73%-20.00%INCRInterCure0.00%+5.12%-1.49%+2.01%-33.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals1.6483 of 5 stars3.50.00.00.02.01.70.6CARMCarisma Therapeutics2.4902 of 5 stars3.25.00.00.00.61.70.6IKNAIkena Oncology3.5936 of 5 stars3.35.00.00.03.61.71.3INCRInterCure0.4283 of 5 stars0.03.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$6.33427.78% UpsideCARMCarisma Therapeutics 2.43Hold$1.93336.41% UpsideIKNAIkena Oncology 2.50Moderate Buy$3.00120.59% UpsideINCRInterCure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CARM, ABOS, INCR, and IKNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.004/1/2025CARMCarisma TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $1.003/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/ACARMCarisma Therapeutics$19.63M0.94N/AN/A($0.67) per share-0.66IKNAIkena Oncology$9.16M7.17N/AN/A$2.61 per share0.52INCRInterCure$64.55M1.07N/AN/A$2.36 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)CARMCarisma Therapeutics-$60.48M-$1.56N/AN/AN/A-254.28%-957.20%-137.38%8/6/2025 (Estimated)IKNAIkena Oncology-$49.23M-$0.86N/AN/AN/AN/A-30.59%-27.55%8/14/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)Latest CARM, ABOS, INCR, and IKNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/13/2025Q1 2025CARMCarisma Therapeutics-$0.17-$0.22-$0.05-$0.22$2.47 million$3.65 million5/8/2025Q1 2025IKNAIkena Oncology-$0.21-$0.18+$0.03-$0.18N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACARMCarisma TherapeuticsN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.198.028.02CARMCarisma TherapeuticsN/A1.341.34IKNAIkena OncologyN/A13.3113.31INCRInterCure0.341.731.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CARMCarisma Therapeutics44.27%IKNAIkena Oncology75.00%INCRInterCure8.34%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%CARMCarisma Therapeutics12.57%IKNAIkena Oncology5.94%INCRInterCure0.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million54.94 millionOptionableCARMCarisma Therapeutics2041.79 million36.54 millionNo DataIKNAIkena Oncology7048.26 million45.39 millionNot OptionableINCRInterCure35045.57 million45.46 millionOptionableCARM, ABOS, INCR, and IKNA HeadlinesRecent News About These CompaniesShort Interest in InterCure Ltd. (NASDAQ:INCR) Increases By 26.9%June 18, 2025 | marketbeat.comInterCure (NASDAQ:INCR) Stock Price Up 1.9% - What's Next?June 5, 2025 | marketbeat.comInterCure Ltd. (NASDAQ:INCR) Short Interest Up 21.5% in MayJune 4, 2025 | marketbeat.comInterCure Reports Strong Start to 2025 Amid Recovery EffortsMay 1, 2025 | tipranks.comInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025May 1, 2025 | prnewswire.comInterCure names Alexander Rabinovich as Chairman, replacing Ehud BarakFebruary 15, 2025 | markets.businessinsider.comInterCure Names Alexander Rabinovich as Chairman Replacing Ehud BarakFebruary 12, 2025 | prnewswire.comInterCure Secures Major Funding to Boost GrowthDecember 22, 2024 | markets.businessinsider.comCannabis co InterCure raising NIS 66m for Nir Oz facilityDecember 22, 2024 | en.globes.co.ilInterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz FacilityDecember 20, 2024 | prnewswire.comRising High: Exclusive talk with house of brands Carma HoldCoNovember 7, 2024 | markets.businessinsider.comInterCure Ltd. (INCR)October 16, 2024 | finance.yahoo.comAre Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed CompanySeptember 14, 2024 | benzinga.comInterCure partners with Cookies to launch cannabis pharmacies in GermanyAugust 30, 2024 | investing.comTop Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On GermanyAugust 30, 2024 | msn.comInterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionAugust 30, 2024 | finanznachrichten.deInterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionAugust 29, 2024 | globenewswire.comInterCure Announces Expansion of its Strategic partnership with Cookies to GermanyAugust 28, 2024 | finance.yahoo.comElectreon Wireless Ltd (ELWS)July 31, 2024 | investing.comAsset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQMay 24, 2024 | markets.businessinsider.comInterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis ConferenceMay 22, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherSalesforce Raises Prices: 3 Reasons Its Stock Price Will FollowBy Thomas Hughes | June 18, 2025View Salesforce Raises Prices: 3 Reasons Its Stock Price Will FollowSalesforce’s Stock Price Presents an Opportunity to BuyBy Thomas Hughes | May 29, 2025View Salesforce’s Stock Price Presents an Opportunity to BuyAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayQualcomm: A Technical Setup Is Emerging, and It's BullishBy Sam Quirke | June 18, 2025View Qualcomm: A Technical Setup Is Emerging, and It's BullishCARM, ABOS, INCR, and IKNA Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.20 -0.02 (-1.64%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.21 +0.01 (+0.83%) As of 06/20/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Carisma Therapeutics NASDAQ:CARM$0.44 -0.06 (-12.18%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.45 +0.00 (+1.11%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Ikena Oncology NASDAQ:IKNA$1.36 -0.01 (-0.73%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.84%) As of 06/20/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.InterCure NASDAQ:INCR$1.52 +0.02 (+1.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 06/20/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
